Annual report pursuant to Section 13 and 15(d)

Note 1 - Business

v3.20.1
Note 1 - Business
12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]
1.
Business
 
DiaMedica Therapeutics Inc. and its wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. (collectively “we,” “us,” “our,” “DiaMedica” and the “Company”), exist for the primary purpose of advancing the clinical and commercial development of a proprietary recombinant
KLK1
protein for the treatment of kidney and neurological diseases. Currently, our primary focus is on chronic kidney disease (CKD) and acute ischemic stroke (AIS). Our parent company is governed under the British Columbia Business Corporations Act and, commencing on
December 7, 2018,
our common shares are publicly traded on The Nasdaq Capital Market under the symbol “DMAC.” The Company’s shares were previously traded on the TSX Venture Exchange in Canada and on the OTCQB in the United States.
 
Effective
November 15, 2018,
we implemented a
1
-for-
20
consolidation of our common shares.
No
fractional shares were issued in connection with the share consolidation. Instead, the Company rounded to the nearest whole number the number of shares shareholders were entitled to receive in connection with the consolidation. The share consolidation was approved by our shareholders as of
November 6, 2018
and was implemented to increase the market price per common share to a level that qualified for listing on The Nasdaq Capital Market. Proportional adjustments were also made to common shares reserved for issuance under the Company’s equity-based compensation plans and outstanding stock options, deferred share units and warrants. All references to share and per share amounts included in these consolidated financial statements have been retroactively restated to reflect the share consolidation.